Lymph node metastases: importance of detection and treatment strategies

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer. 2016;139(11):2436–2446.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14(2):13–16.
   Google Scholar
• Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer. 1977;40(Suppl 1):574–587.
   PubMed Web of Science ®Google Scholar
• Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996;14(4):1048–1054.
   PubMed Web of Science ®Google Scholar
• Burish TG, Lyles JN. Effectiveness of relaxation training in reducing adverse reactions to cancer chemotherapy. J Behav Med. 1981;4(1):65–78.
   PubMedGoogle Scholar
• Chen Y, Song G, Dong Z, et al. Drug‐loaded mesoporous tantalum oxide nanoparticles for enhanced synergetic chemoradiotherapy with reduced systemic toxicity. Small. 2017;13. DOI:10.1002/smll.201602869
   Web of Science ®Google Scholar
• Fass L. Imaging and cancer: a review. Mol Oncol. 2008;2(2):115–152.
   PubMed Web of Science ®Google Scholar
• Frangioni JV. New technologies for human cancer imaging. J Clin Oncol. 2008;26(24):4012–4021.
   PubMed Web of Science ®Google Scholar
• Charman WN, Stella VJ. Lymphatic transport of drugs. Florida (FL): C.R.C. Press; 1992.
   Google Scholar
• Olszewski WL. The lymphatic system in body homeostasis: physiological conditions. Lymphatic Res Biol. 2004;1(1):11–24.
   Google Scholar
• Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50(1–2):3–20.
   PubMed Web of Science ®Google Scholar
• McGeown JG, Symmers W. The lymphatic vessels. In thymus, lymph nodes, spleen and lymphatics, (systemic pathology 7). New York (NY): Symmers; 1992.
   Google Scholar
• Lane K, Worsley D, McKenzie D. Exercise and the lymphatic system. Sports Med. 2005;35(6):461–471.
   PubMed Web of Science ®Google Scholar
• Szuba A, Rockson SG. Lymphedema: anatomy, physiology and pathogenesis. Vasc Med. 1997;2(4):321–326.
   PubMedGoogle Scholar
• Clément O, Luciani A. Imaging the lymphatic system: possibilities and clinical applications. Eur Radiol. 2004;14(8):1498–1507.
   PubMed Web of Science ®Google Scholar
• Schmid-Schönbein GW. Microlymphatics and lymph flow. Physiol Rev. 1990;70(4):987–1028.
   PubMed Web of Science ®Google Scholar
• Muthuchamy M, Zawieja D. Molecular regulation of lymphatic contractility. Ann N Y Acad Sci. 2008;1131:89–99.
   PubMed Web of Science ®Google Scholar
• Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol. 2006;126(10):2167–2177.
   PubMed Web of Science ®Google Scholar
• Gashev AA. Physiologic aspects of lymphatic contractile function. Ann N Y Acad Sci. 2002;979:178–187.
   PubMed Web of Science ®Google Scholar
• Von Der Weid P-Y, Rainey KJ. Review article: lymphatic system and associated adipose tissue in the development of inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32(6):697–711.
   PubMed Web of Science ®Google Scholar
• Katakai T, Hara T, Lee J-H, et al. A novel reticular stromal structure in lymph node cortex: an immuno-platform for interactions among dendritic cells, T cells and B cells. Int Immunol. 2004;16(8):1133–1142.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252.
   PubMed Web of Science ®Google Scholar
• Willard-Mack CL. Normal structure, function, and histology of lymph nodes. Toxicol Pathol. 2006;34(5):409–424.
   PubMed Web of Science ®Google Scholar
• Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech. 2001;55(2):92–99.
   PubMed Web of Science ®Google Scholar
• Chua B, Ung O, Taylor R, et al. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg. 2001;71(12):723–728.
   PubMed Web of Science ®Google Scholar
• Cunnick GH, Jiang WG, Gomez KF, et al. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol. 2002;17(3):863–870.
   PubMed Web of Science ®Google Scholar
• Paduch R. The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol. 2016;39(5):397–410.
   PubMed Web of Science ®Google Scholar
• Kawada K, Taketo MM. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res. 2011;71(4):1214–1218.
   PubMed Web of Science ®Google Scholar
• Laurent TC, Fraser JR. Hyaluronan. FASEB J. 1992;6(79):2397–2404.
   PubMedGoogle Scholar
• Ran S, Volk L, Hall K, et al. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology. 2010;17(4):229–251.
   PubMedGoogle Scholar
• Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 2010;140(4):460–476.
   PubMed Web of Science ®Google Scholar
• Karaman S, Detmar M. Mechanisms of lymphatic metastasis. J Clin Invest. 2014;124(3):922–928.
   PubMed Web of Science ®Google Scholar
• Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 2008;216(2):347–354.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Williams SP, Karnezis T, et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer. 2014;14:159–172.
   PubMed Web of Science ®Google Scholar
• McAllaster JD, Cohen MS. Role of the lymphatics in cancer metastasis and chemotherapy applications. Adv Drug Deliv Rev. 2011;63(10–11):867–875.
   PubMed Web of Science ®Google Scholar
• Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor‐3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20(6):1223–1231.
   PubMed Web of Science ®Google Scholar
• Mäkinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3. EMBO J. 2001;20(17):4762–4773.
   PubMed Web of Science ®Google Scholar
• Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998;95(2):548–553.
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15(2):290–298.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186–191.
   PubMed Web of Science ®Google Scholar
• He Y, Kozaki K-I, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002;94(11):819–825.
   PubMedGoogle Scholar
• Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005;65(15):6901–6909.
   PubMed Web of Science ®Google Scholar
• Zhang D, Li B, Shi J, et al. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)–A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res. 2010;70(6):2495–2503.
   PubMed Web of Science ®Google Scholar
• Xie Y, Bagby TR, Cohen MS, et al. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv. 2009;6(8):785–792.
   PubMed Web of Science ®Google Scholar
• Singh I, Swami R, Khan W, et al. Lymphatic system: a prospective area for advanced targeting of particulate drug carriers. Expert Opin Drug Deliv. 2014;11(2):211–229.
   PubMed Web of Science ®Google Scholar
• Khan AA, Mudassir J, Mohtar N, et al. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed. 2013;8:2733–2744.
   PubMed Web of Science ®Google Scholar
• Cueni LN, Detmar M. The lymphatic system in health and disease. Lymphatic Res Biol. 2008;6(3–4):109–122.
   PubMedGoogle Scholar
• Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–118.
   PubMed Web of Science ®Google Scholar
• Fife K, Thompson JF. Lymph-node metastases in patients with melanoma: what is the optimum management? Lancet Oncol. 2001;2(10):614–621.
   PubMed Web of Science ®Google Scholar
• Zhang X-Y, Lu W-Y. Recent advances in lymphatic targeted drug delivery system for tumor metastasis. Cancer Biol Med. 2014;11(4):247–254.
   PubMedGoogle Scholar
• Ryan GM, Kaminskas LM, Bulitta JB, et al. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. J Control Release. 2013;172(1):128–136.
   PubMed Web of Science ®Google Scholar
• Rovera F, Frattini F, Marelli M, et al. Axillary sentinel lymph node biopsy: an overview. Int J Surg. 2008;6:S109–S112.
   PubMedGoogle Scholar
• Wang Y, Dong H, Wu H, et al. Improved false negative rate of axillary status using sentinel lymph node biopsy and ultrasound-suspicious lymph node sampling in patients with early breast cancer. BMC Cancer. 2015;15(1):382.
   PubMedGoogle Scholar
• Porcu EP, Salis A, Gavini E, et al. Indocyanine green delivery systems for tumour detection and treatments. Biotechnol Adv. 2016;34(5):768–789.
   PubMed Web of Science ®Google Scholar
• Giunchedi P, Gavini E, Dionigi P, et al. Selective targeting of liver nodules. Present situation and new challenges to enhance indocyanine green captation from colorectal liver metastases. Curr Drug Deliv. 2015;12(5):474–476.
   PubMed Web of Science ®Google Scholar
• Miura Y, Mikada M, Ouchi T, et al. Early diagnosis of lymph node metastasis: importance of intranodal pressures. Cancer Sci. 2016;107(3):224–232.
   PubMed Web of Science ®Google Scholar
• Emile SH, Elfeki H, Shalaby M, et al. Sensitivity and specificity of indocyanine green near‐infrared fluorescence imaging in detection of metastatic lymph nodes in colorectal cancer: systematic review and meta‐analysis. J Surg Oncol. 2017;116:730–740.
   PubMed Web of Science ®Google Scholar
• Guo J, Yang H, Wang S, et al. Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol. 2017;15(1):196.
   PubMedGoogle Scholar
• Taşkın S, Şükür YE, Altın D, et al. Laparoscopic near-infrared fluorescent imaging as an alternative option for sentinel lymph node mapping in endometrial cancer: a prospective study. Int J Surg. 2017;47:13–17.
   PubMed Web of Science ®Google Scholar
• Proulx ST, Luciani P, Dieterich LC, et al. Expansion of the lymphatic vasculature in cancer and inflammation: new opportunities for in vivo imaging and drug delivery. J Control Release. 2013;172(2):550–557.
   PubMed Web of Science ®Google Scholar
• Cuenca AG, Jiang H, Hochwald SN, et al. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107(3):459–466.
   PubMed Web of Science ®Google Scholar
• Li T, Zhang Y, Meng Y-P, et al. miR-542-3p appended sorafenib/all-trans retinoic acid (ATRA)-loaded lipid nanoparticles to enhance the anticancer efficacy in gastric cancers. Pharm Res. 2017;34(12):2710–2719.
   PubMed Web of Science ®Google Scholar
• He Z, Huang J, Xu Y, et al. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer. Oncotarget. 2015;6(39):42150–42168.
   PubMed Web of Science ®Google Scholar
• Yang Y, He L, Liu Y, et al. Promising nanocarriers for PEDF gene targeting delivery to cervical cancer cells mediated by the over-expressing FRα. Sci Rep. 2016;6:32427.
   PubMed Web of Science ®Google Scholar
• Li J, Wu C, Hou P, et al. One-pot preparation of hydrophilic manganese oxide nanoparticles as T1 nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo. Biosens Bioelectron. 2018;102:1–8.
   PubMed Web of Science ®Google Scholar
• Jaskula-Sztul R, Chen G, Dammalapati A, et al. AB3-loaded and tumor-targeted unimolecular micelles for medullary thyroid cancer treatment. J Mater Chem B. 2017;5(1):151–159.
   PubMed Web of Science ®Google Scholar
• Ryan GM, Kaminskas LM, Porter CJ. Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. J Control Release. 2014;193:241–256.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135–146.
   PubMed Web of Science ®Google Scholar
• Maeda H, Tsukigawa K, Fang J. A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next‐generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects. Microcirculation. 2016;23(3):173–182.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda HA. New concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12):6387–6392.
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Targeting. 2007;15(7–8):457–464.
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting in cancer nanotechnology: methods and protocols. In: Grobmyer SR, Moudgil BM, editors. Cancer Nanotechnology. Methods in Molecular Biology (Methods and Protocols). New York (US): Humana Press, Springer Protocols; 2010;624:25–37.
   Google Scholar
• Nakamura Y, Mochida A, Choyke PL, et al. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem. 2016;27(10):2225–2238.
   PubMed Web of Science ®Google Scholar
• Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev. 1995;17(1):129–148.
   Web of Science ®Google Scholar
• Nune SK, Gunda P, Majeti BK, et al. Advances in lymphatic imaging and drug delivery. Adv Drug Deliv Rev. 2011;63(10–11):876–885.
   PubMed Web of Science ®Google Scholar
• Reddy ST, Van Der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25:1159–1164.
   PubMed Web of Science ®Google Scholar
• Oussoren C, Zuidema J, Crommelin DJA, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta Biomembr. 1997;1328(2):261–272.
   PubMed Web of Science ®Google Scholar
• Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev. 2012;92(3):1005–1060.
   PubMed Web of Science ®Google Scholar
• Bagby TR, Duan S, Cai S, et al. Lymphatic trafficking kinetics and near-infrared imaging using star polymer architectures with controlled anionic character. Eur J Pharm Sci. 2012;47(1):287–294.
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Porter CJ. Targeting the lymphatics using dendritic polymers (dendrimers). Adv Drug Deliv Rev. 2011;63(10):890–900.
   PubMed Web of Science ®Google Scholar
• Rao DA, Forrest ML, Alani AW, et al. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci. 2010;99(4):2018–2031.
   PubMed Web of Science ®Google Scholar
• Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7(2):167–169.
   PubMed Web of Science ®Google Scholar
• Bagby TR, Cai S, Duan S, et al. Impact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent. Pharmaceutics. 2012;4(2):276–295.
   PubMedGoogle Scholar
• Trubetskoy VS, Torchilin VP. New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes. J Liposome Res. 1994;4(2):961–980.
   Google Scholar
• Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release. 2004;94(1):155–161.
   PubMed Web of Science ®Google Scholar
• Lawson KA, Anderson K, Snyder RM, et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol. 2004;54(5):421–431.
   PubMed Web of Science ®Google Scholar
• Shmeeda H, Mak L, Tzemach D, et al. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther. 2006;5(4):818–824.
   PubMed Web of Science ®Google Scholar
• Ichihara H, Ueno J, Umebayashi M, et al. Chemotherapy with hybrid liposomes for acute lymphatic leukemia leading to apoptosis in vivo. Int J Pharm. 2011;406(1–2):173–178.
   PubMedGoogle Scholar
• Cai S, Yang Q, Bagby TR, et al. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63(10–11):901–908.
   PubMed Web of Science ®Google Scholar
• Toyota T, Fujito H, Suganami A, et al. Near-infrared-fluorescence imaging of lymph nodes by using liposomally formulated indocyanine green derivatives. Bioorg Med Chem. 2014;22(2):721–727.
   PubMed Web of Science ®Google Scholar
• Yan Z, Zhan C, Wen Z, et al. LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics. Nanotechnology. 2011;22(41):415103–415111.
   PubMed Web of Science ®Google Scholar
• Ye T, Zhang H, Chen G, et al. Fluorescent molecular imaging of metastatic lymph node using near‐infrared emitting low molecular weight heparin modified nanoliposome based on enzyme-substrate interaction. Contrast Media Mol Imaging. 2016;11(6):482–491.
   PubMed Web of Science ®Google Scholar
• Xiao K, Luo J, Li Y, et al. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Release. 2011;155(2):272–281.
   PubMed Web of Science ®Google Scholar
• Rafi M, Cabral H, Kano MR, et al. Polymeric micelles incorporating (1, 2-diaminocyclohexane) platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J Control Release. 2012;159(2):189–196.
   PubMed Web of Science ®Google Scholar
• Lee C, Kim J, Zhang Y, et al. Dual-color photoacoustic lymph node imaging using nanoformulated naphthalocyanines. Biomaterials. 2015;73:142–148.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Kawamoto S, Brechbiel MW, et al. Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle. Neoplasia. 2005;7(11):984–991.
   PubMed Web of Science ®Google Scholar
• Koyama Y, Talanov VS, Bernardo M, et al. A dendrimer-based nanosized contrast agent dual‐labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging. 2007;25(4):866–871.
   PubMed Web of Science ®Google Scholar
• Cai S, Xie Y, Bagby TR, et al. Intralymphatic chemotherapy using a hyaluronan–cisplatin conjugate. J Surg Res. 2008;147(2):247–252.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Cai S, Xie Y, et al. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg. 2009;198(6):781–786.
   PubMedGoogle Scholar
• Cai S, Xie Y, Davies NM, et al. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. J Pharm Sci. 2010;99(6):2664–2671.
   PubMed Web of Science ®Google Scholar
• Lee E-H, Kim J-K, Lim J-S, et al. Enhancement of indocyanine green stability and cellular uptake by incorporating cationic lipid into indocyanine green-loaded nanoemulsions. Colloids Surf B. 2015;136:305–313.
   PubMed Web of Science ®Google Scholar
• Mok H, Jeong H, Kim S-J, et al. Indocyanine green encapsulated nanogels for hyaluronidase activatable and selective near infrared imaging of tumors and lymph nodes. Chem Commun. 2012;48:8628–8630.
   PubMed Web of Science ®Google Scholar
• Yang F, Jin C, Yang D, et al. Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment. Eur J Cancer. 2011;47(12):1873–1882.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Ogawa M, Kosaka N, et al. Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine. 2009;4(4):411–419.
   PubMed Web of Science ®Google Scholar
• Rhyner MN, Smith AM, Gao X, et al. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine. 2006;1(2):209–217.
   PubMed Web of Science ®Google Scholar
• Cho K, Wang XU, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–1316.
   PubMed Web of Science ®Google Scholar